BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1368 related articles for article (PubMed ID: 17614338)

  • 21. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
    Denham JW; Kumar M; Gleeson PS; Lamb DS; Joseph D; Atkinson C; Matthews J; Tai KH; Spry NA; Christie D; Turner S; Greer PB; D'Este C; Steigler A
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):404-11. PubMed ID: 19176272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].
    Quero L; Mongiat-Artus P; Ravery V; Hennequin V; Maylin C; Desgrandchamps F; Hennequin C
    Cancer Radiother; 2009 Jul; 13(4):267-75. PubMed ID: 19446487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
    Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
    Horwitz EM; Thames HD; Kuban DA; Levy LB; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Hanks GE; Zietman AL
    J Urol; 2005 Mar; 173(3):797-802. PubMed ID: 15711272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
    Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.
    Abramowitz MC; Li T; Buyyounouski MK; Ross E; Uzzo RG; Pollack A; Horwitz EM
    Cancer; 2008 Jan; 112(1):55-60. PubMed ID: 17968996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer.
    Strom SS; Kamat AM; Gruschkus SK; Gu Y; Wen S; Cheung MR; Pisters LL; Lee AK; Rosser CJ; Kuban DA
    Cancer; 2006 Aug; 107(3):631-9. PubMed ID: 16802288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.
    Horwitz EM; Uzzo RG; Hanlon AL; Greenberg RE; Hanks GE; Pollack A
    J Urol; 2003 Jun; 169(6):2153-7; discussion 2157-9. PubMed ID: 12771738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    Palma D; Pickles T; Tyldesley S;
    BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
    Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.